Document is current
Any future updates will be listed below
-
Authors
Rothstein, Jeffrey D. https://orcid.org/0000-0003-2001-8470
Keeley, Olivia
Warlick, Caroline
Miller, Timothy M.
Ly, Cindy V. https://orcid.org/0000-0002-7063-5170
Glass, Jonathan D. https://orcid.org/0000-0002-3295-4971
Coyne, Alyssa N. https://orcid.org/0000-0002-3658-5325
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS132836)
- License Information
-
More Information
Article History
Received: 29 April 2025
Accepted: 22 July 2025
First Online: 2 August 2025
Competing interests
: A.N.C. (50%) and J.D.R. (50%) are inventors on US patent application number 63/111,882 filed by Johns Hopkins University on methods to modulate CHMP7 expression as a therapy for neurodegeneration. A.N.C. (75%) and J.D.R. (25%) are inventors on US patent application number 63/605,054 filed by Johns Hopkins University on methods to increase/restore expression of POM121 for mitigation of NPC injury and TDP-43 dysfunction in neurodegeneration. The remaining authors declare no competing interests.
